Psilocybin reshapes cortical inhibition through selective interneuron recruitment

This study demonstrates that psilocybin selectively modulates cortical inhibition in the mouse medial frontal cortex by activating 5-HT1A receptors on somatostatin-expressing interneurons to suppress their activity while simultaneously enhancing parvalbumin-expressing interneuron firing, thereby reshaping neural dynamics to drive long-term behavioral effects.

The Gist

Imagine your brain is a bustling city. In this city, there are two main types of workers: the Excitatory Workers (Pyramidal cells) who keep the construction going, and the Inhibitory Supervisors (GABAergic neurons) who make sure the construction doesn't get out of hand.

For a long time, scientists thought that magic mushrooms (specifically psilocybin) only talked to the Excitatory Workers. But this new study reveals that psilocybin is actually a master conductor who gives very specific instructions to different types of Supervisors, completely reshaping how the city operates.

Here is the story of what happens when psilocybin enters the brain, explained simply:

1. The Three Types of Supervisors

In the brain's "front office" (the medial frontal cortex), there are three main types of Inhibitory Supervisors, each with a different job:

• The "SST" Supervisors: They stand at the dendrites (the receiving antennas) of the Excitatory Workers. Their job is to block signals coming in. Think of them as the bouncers at the front door.
• The "PV" Supervisors: They stand right next to the cell body (the main office) of the Excitatory Workers. Their job is to stop the workers from firing too fast. Think of them as the security guards inside the building.
• The "VIP" Supervisors: They are the managers who tell the SST bouncers to take a break.

2. The Psilocybin Effect: A Tale of Two Supervisors

When psilocybin enters the city, it doesn't treat all supervisors the same. It plays a game of "opposites":

• It tells the SST Bouncers to go home.
  Psilocybin hits a specific switch (the 5-HT1A receptor) on the SST supervisors. This switch acts like a "sleep" button. The SST supervisors stop blocking the front door. Suddenly, the Excitatory Workers start receiving a flood of new signals and ideas. This "opening up" is likely why people feel more creative or see new connections during a trip. It also helps the brain "unlearn" old fears.
• It tells the PV Security Guards to work overtime.
  While the front door is open, psilocybin wakes up the PV guards inside. They start working harder to make sure the Excitatory Workers don't go crazy and start firing randomly. They keep the chaos contained so the brain doesn't short-circuit.

The Result: The brain gets a "safe opening." The doors are open to new ideas (less inhibition at the front), but the internal security is tight (more inhibition at the core). This balance allows for plasticity (learning) without losing control.

3. The VIP Managers Stay Asleep

The researchers checked to see if the VIP managers were involved. They thought, "Maybe psilocybin wakes up the VIPs, who then tell the SST bouncers to leave?"
The answer was no. The VIP managers didn't change their activity at all. This proves that psilocybin isn't using a middleman; it goes straight to the SST bouncers and tells them to stop working directly.

4. Why This Matters for Depression and Trauma

The study went a step further to see what happens if you remove that specific "sleep switch" (the 5-HT1A receptor) from the SST bouncers.

• The Head Twitch: When mice got psilocybin, they did a little head shake (a sign of the drug working). Even without the switch, they still shook their heads. This means the immediate psychedelic feeling doesn't need this specific switch.
• The Long-Term Healing: However, when it came to fear and stress, the story changed.
  • Normal Mice: Psilocybin helped them forget their fears and reduced their stress (like a therapy session).
  • Mice without the Switch: Psilocybin did nothing for their stress or fear. They remained stuck in their old patterns.

The Metaphor: Think of the 5-HT1A receptor on the SST bouncers as the "Key to the Therapy Room." Psilocybin can make you feel weird (the head twitch) without this key, but it cannot help you heal your trauma or depression without it.

Summary

This paper tells us that psilocybin is a precise tool, not a blunt hammer.

1. It silences the "dendritic bouncers" (SST) to let new ideas in.
2. It activates the "somatic guards" (PV) to keep things stable.
3. It does this directly via a specific receptor (5-HT1A), not through a chain of command.
4. This specific mechanism is crucial for the long-term healing of depression and fear, which is why it's such a promising treatment for mental health.

In short: Psilocybin opens the windows to let fresh air in, but it also locks the doors to keep the storm out, and it does this by talking directly to the specific staff members who control those windows and doors.

Technical Summary

1. Problem Statement

While psychedelics like psilocybin show significant therapeutic potential for psychiatric disorders (e.g., depression), the neurobiological mechanisms underlying their effects remain incompletely understood.

• Current Gap: Most research has focused on the drug's interaction with excitatory cortical pyramidal cells. However, classic psychedelics are agonists at multiple serotonin receptors (5-HT1A, 5-HT2A, 5-HT2C) that are also expressed on cortical inhibitory GABAergic neurons.
• Specific Question: How does psilocybin specifically alter the in vivo firing dynamics of major GABAergic interneuron subtypes (Somatostatin-expressing [SST], Parvalbumin-expressing [PV], and Vasoactive Intestinal Peptide-expressing [VIP]) in the medial frontal cortex? Furthermore, which specific receptor pathways mediate these effects and subsequent long-term behavioral changes?

2. Methodology

The study employed a multi-modal approach combining in vivo electrophysiology, two-photon calcium imaging, genetic manipulation, and behavioral assays in mice.

• Animal Models:
  • Cell-Type Specificity: Used Cre-driver lines (SstCre, PvalbCre, VipCre) crossed with Ai32 reporter mice (expressing ChR2-eYFP) for opto-tagging.
  • Conditional Knockout (cKO): Generated SstCre/+;Htr1afl/fl mice (SST-1A cKO) to delete the 5-HT1A receptor specifically in SST interneurons.
• In Vivo Electrophysiology (Neuropixels):
  • Recorded spontaneous spiking from genetically identified interneurons in the awake, head-fixed mouse medial frontal cortex (mFC).
  • Opto-tagging: Used laser pulses to confirm cell identity (ChR2-expressing units).
  • Protocol: Recorded 30 min baseline, administered psilocybin (1 mg/kg, i.p.) or saline, and recorded for 60 min post-injection.
  • Pharmacology: In a subset, the 5-HT1A antagonist WAY-100635 was administered prior to psilocybin to test receptor involvement.
• Two-Photon Calcium Imaging:
  • Used AAV-mediated expression of GCaMP6f in VipCre, SstCre, and PvalbCre mice to image somatic calcium transients in Layer 2/3 of the mFC.
  • Compared pre- and post-drug calcium event rates in VIP, SST, and PV interneurons.
• Molecular Validation:
  • RNAscope: Used fluorescence in situ hybridization to quantify Htr1a transcript expression in SST cells in control vs. SST-1A cKO mice.
• Behavioral Assays:
  • Fear Extinction: Tested fear conditioning, extinction, retention, and renewal to assess stress-related plasticity.
  • Tail Suspension Test (TST): Assessed antidepressant-like effects (immobility time) 24 hours post-drug.
  • Head-Twitch Response (HTR): Measured acute psychedelic potency.

3. Key Contributions

• Cell-Type Specific Dynamics: First comprehensive in vivo characterization showing that psilocybin has opposing effects on the two major GABAergic populations in the mFC: it suppresses SST interneurons while activating PV interneurons.
• Mechanistic Dissection: Identified the 5-HT1A receptor on SST interneurons as the primary driver for the drug-induced suppression of SST activity, ruling out the disinhibitory VIP-SST circuit as the primary mechanism.
• Behavioral Link: Demonstrated that the 5-HT1A receptor on SST interneurons is essential for the long-term therapeutic effects (fear extinction and antidepressant-like behavior) of psilocybin, but not for the acute hallucinogenic-like head-twitch response.

4. Key Results

A. Differential Effects on Interneuron Firing (Electrophysiology)

• SST Interneurons: Psilocybin caused a significant acute reduction in firing rates (approx. 33% decrease) in SST interneurons.
• PV Interneurons: In contrast, psilocybin caused a significant increase in firing rates in PV interneurons (approx. 90% increase), peaking ~15 minutes post-injection.
• VIP Interneurons: No significant change in activity was observed in VIP interneurons, suggesting the VIP-mediated disinhibitory circuit is not the primary driver of SST suppression.

B. Mechanism of Action (Receptor Specificity)

• Transcriptomics: Single-cell sequencing data confirmed SST interneurons express high levels of Htr1a (5-HT1A), while PV cells express Htr2a and VIP cells express Htr2c.
• Pharmacological Blockade: Pre-treatment with the 5-HT1A antagonist WAY-100635 completely abolished the psilocybin-induced suppression of SST interneurons.
• Genetic Knockout: In SST-1A cKO mice (where Htr1a is deleted in SST cells), psilocybin failed to reduce SST firing rates. This confirmed that direct activation of 5-HT1A receptors on SST interneurons is necessary for the suppression.

C. Behavioral Consequences

• Fear Extinction: In control mice, psilocybin facilitated fear extinction and retention. In SST-1A cKO mice, this beneficial effect was abolished, indicating that 5-HT1A signaling on SST cells is required for psilocybin's long-term plasticity effects.
• Antidepressant Effect: Psilocybin reduced immobility in the Tail Suspension Test in controls but had no effect in SST-1A cKO mice.
• Acute Response: The Head-Twitch Response (HTR) was robust in both control and SST-1A cKO mice, indicating that the acute hallucinogenic effect is independent of 5-HT1A receptors on SST interneurons.

5. Significance and Discussion

• Redefining the Mechanism: The study proposes a model where psilocybin creates a coordinated shift in cortical inhibition:
  1. Dendritic Disinhibition: By suppressing SST interneurons (which target pyramidal dendrites), psilocybin reduces dendritic inhibition, potentially facilitating synaptic plasticity and learning (e.g., fear extinction).
  2. Perisomatic Control: By activating PV interneurons (which target pyramidal somas), psilocybin increases perisomatic inhibition, preventing runaway excitation and maintaining network stability.
• Therapeutic Implications: The dissociation between acute effects (HTR) and long-term therapeutic effects (extinction/antidepressant) suggests that the therapeutic benefits of psychedelics rely on specific microcircuit remodeling mediated by SST interneurons, rather than just global receptor activation.
• Comparison to Ketamine: Unlike NMDA receptor antagonists (e.g., ketamine) which reduce perisomatic inhibition, psilocybin increases it (via PV activation), highlighting distinct microcircuit mechanisms for different classes of rapid-acting antidepressants.

Conclusion: Psilocybin reshapes cortical inhibition by selectively recruiting interneuron populations via specific serotonin receptors. The suppression of SST interneurons via 5-HT1A receptors is a critical, cell-type-specific mechanism required for the drug's long-term behavioral efficacy in treating stress-related disorders.